Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report

Ann Oncol. 2020 Jul;31(7):961-964. doi: 10.1016/j.annonc.2020.03.300. Epub 2020 Apr 2.

Authors

J-M Michot¹, L Albiges², N Chaput³, V Saada⁴, F Pommeret², F Griscelli⁴, C Balleyguier⁵, B Besse², A Marabelle⁶, F Netzer⁷, M Merad², C Robert², F Barlesi², B Gachot⁸, A Stoclin⁸

Affiliations

¹ Department of Therapeutic Innovation and Early Testing. Electronic address: [email protected].
² Medical Oncology, University Paris Saclay, Gustave Roussy.
³ Molecular Analysis, modélisation et imagerie de la Maladie cancéreuse, Laboratoire d'Immunomonitoring en Oncologie, Gustave Roussy, INSERM, CNRS.
⁴ Department of Biology, University Paris Saclay, Gustave Roussy.
⁵ Department of Medical Imaging.
⁶ Department of Therapeutic Innovation and Early Testing.
⁷ Department of Pharmacy, Villejuif, France.
⁸ Intensive Care Department, Université Paris-Saclay, Gustave Roussy Villejuif, France.

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Antibodies, Monoclonal, Humanized / therapeutic use*
Autoantibodies / therapeutic use*
Betacoronavirus*
COVID-19
Coronavirus Infections / complications
Coronavirus Infections / diagnostic imaging
Coronavirus Infections / drug therapy*
Humans
Male
Pandemics
Pneumonia, Viral / complications
Pneumonia, Viral / diagnostic imaging
Pneumonia, Viral / drug therapy*
Receptors, Interleukin-6* / antagonists & inhibitors
Respiratory Insufficiency / diagnostic imaging
Respiratory Insufficiency / drug therapy*
Respiratory Insufficiency / etiology
SARS-CoV-2
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
Autoantibodies
Receptors, Interleukin-6
tocilizumab